The Science of Longevity Research: What We Know in 2026
August 5, 2026 · Frisian News
The longevity industry raises billions to develop drugs that work in mice but fail in humans. The honest truth: we don't yet know how to extend human lifespan.
The longevity biotech industry raised $5 billion last year, yet almost every drug that reverses aging in mice has failed in humans. Researchers tested compounds targeting cellular senescence, NAD+ pathways, and protein folding for decades now. The gap between lab mouse and living person remains as wide as ever.
Who owns these companies? Mostly Silicon Valley venture capital and tech billionaires. They fund the research, hire the best scientists, and hold the patents. If someone does crack human longevity, the patents will make a few people obscenely rich. And the treatments will cost more than most people earn in a year.
The honest science says we don't know yet. We can't slow aging in humans. NAD+ boosters show promise in mice and weak human studies. Senolytics cleared senescent cells in some trials but no one has lived longer. We don't even know if removing old cells extends life or just makes cells younger in the petri dish.
What we know works is boring. Caloric restriction extends life in animals and some human markers look better. Exercise builds muscle and bone. Sleep matters. No billionaire invested in a compound for "sleep more" because there's no patent, no profit.
The longevity industry wants to sell you eternal youth. For now they're selling you hope and expensive supplements. The science will get there eventually. Just not in time for the people funding it.
Published August 5, 2026 · Frisian News